Celldx - Model 360 -Advanced Tumor Profiling Technology for Personalized Targeted Anti-cancer Treatments

• Evaluation of tumor tissue is used for establishing a diagnosis as well as to determine status of therapeutically relevant biomarkers (gene variants, protein expression) which inform selection of targeted anti-cancer agents.
• However, conventional molecular profiling assessments have a limited coverage of variants and each biomarker has to be evaluated in individual tests.
• Advanced, deep molecular profiling of tumors can provide critical insight into the molecular and functional dynamics of the tumor which may not be revealed by conventional tumor assessments. A comprehensive molecular profiling test can identify multiple tumor vulnerabilities as well as resistance mechanisms in a single step. This information can be used by the treating physicians to select the most appropriate and effective treatment strategy with low risks of treatment failure as well as of toxicities associated with treatment failure.

CellDx^™ is based upon the assessment of the core elements and features that sustain and drive the malignancy, i.e., the molecular perturbations and their dynamics. CellDx™’s comprehensive and meticulous assessment of the molecular tumor interactome is designed to provide relevant insight and identifies aspects that have to be addressed while designing patient-specific treatment strategies. This is essential to design more effective treatments with lower risk of failures and toxicities.